Publications by authors named "Rachel A Schmidt"

Platelets are key mediators of thrombosis. Many agonists of platelet activation are known, but fewer endogenous inhibitors of platelets, such as prostacyclin and nitric oxide (NO), have been identified. Acetylcholinesterase inhibitors, such as donepezil, can cause bleeding in patients, but the underlying mechanisms are not well understood.

View Article and Find Full Text PDF

Objective: Reduced blood flow and tissue oxygen tension conditions result from thrombotic and vascular diseases such as myocardial infarction, stroke, and peripheral vascular disease. It is largely assumed that while platelet activation is increased by an acute vascular event, chronic vascular inflammation, and ischemia, the platelet activation pathways and responses are not themselves changed by the disease process. We, therefore, sought to determine whether the platelet phenotype is altered by hypoxic and ischemic conditions.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare platelets from patients with different types of myocardial infarction (STEMI and NSTEMI) to those from healthy individuals, focusing on their characteristics and functions.* -
  • It found that maximum activation of platelets via the thromboxane receptor was higher in STEMI compared to NSTEMI, while certain activation pathways, like those involving extracellular-signal related-kinase 5, were notably increased, particularly in NSTEMI.* -
  • Additionally, levels of matrix metalloproteinase 9 (MMP9) in platelets were significantly higher in MI patients, offering a potentially better biomarker for differentiating between STEMI and NSTEMI than traditionally used markers like troponin
View Article and Find Full Text PDF